GH
$85.18
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; G...
Recent News
How Guardant’s Shield Blood Test Rollout Through Quest Diagnostics (DGX) Has Changed Its Investment Story
Earlier in March 2026, Guardant Health announced that its FDA-approved Shield blood-based colorectal cancer screening test is now widely available for physician order through Quest Diagnostics’ nationwide network, integrating into Quest accounts, electronic health records, and thousands of collection sites across the United States. This collaboration gives Shield access to roughly 650,000 Quest-connected clinician and hospital accounts, potentially reshaping how preventive colorectal cancer...
Guardant Health (GH) Partners With Manulife to Launch Shield Multi-Cancer Detection Test in Asia
Guardant Health Inc. (NASDAQ:GH) is one of the most promising stocks under $100 to buy. On March 16, Guardant Health announced the launch of its Shield multi-cancer detection/MCD test in several Asian markets through a first-of-its-kind partnership with Manulife. This methylation-based blood test is designed to detect ten common types of cancer (including lung, breast, […]
3 Reasons to Avoid GH and 1 Stock to Buy Instead
What a fantastic six months it’s been for Guardant Health. Shares of the company have skyrocketed 46.9%, hitting $86.90. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Why Guardant Health’s (GH) 2026 Screening Story Reinforced Piper Sandler’s Bullish View
Guardant Health, Inc. (NASDAQ:GH) is one of the best growth stocks to buy according to billionaires. As of March 13, 2026, Guardant Health carried a Moderate Buy consensus from 23 analysts, based on 21 Buy ratings, one Hold, and one Sell. The average 12-month price target stood at $122.57, implying about 43% upside from the […]
Here’s Why Artisan Small Cap Fund Bets on Guardant Health (GH)
Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Small Cap Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. Despite strong results […]